KESETT Trial Completion Timeline
The KESETT trial completion date is not explicitly stated in the available evidence, but based on the study design described, it appears to be an ongoing or planned trial without a specified end date in the provided materials. 1
What We Know About KESETT
The KESETT study is described as a three-armed, Bayesian adaptive randomized trial comparing two doses of ketamine plus levetiracetam to levetiracetam alone for treating benzodiazepine-refractory status epilepticus 1. The trial design features:
- Primary outcome assessment at 60 minutes post-intervention
- An ordinal outcome scale ranging from 1 (improving consciousness and seizure cessation) to 5 (life-threatening event/death)
- Bayesian adaptive methodology with response-adaptive randomization
Key Limitations
The evidence provided 1 discusses the statistical methodology and design of the KESETT trial but does not include:
- Estimated enrollment completion date
- Primary completion date
- Study completion date
- Current recruitment status
- Sample size targets
This appears to be a methodological paper describing the trial's analytical approach rather than a trial registration or protocol paper that would typically contain timeline information.
Where to Find Completion Information
To obtain the actual completion date for KESETT, you would need to:
- Check ClinicalTrials.gov or other trial registries using "KESETT" or "ketamine levetiracetam status epilepticus" as search terms
- Contact the study investigators directly
- Review the full trial protocol if publicly available
The statistical methodology paper 1 was published in 2023, suggesting the trial was in planning or early stages at that time, but no definitive timeline is provided in the available evidence.